(Q38439703)

3 September 2017

title

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera (English)

1 reference

3 September 2017

1 reference

1 reference

1 reference

8

Martha Wadleigh

0 references

Ayalew Tefferi

1

object named as

Ayalew Tefferi

1 reference

3 September 2017

3

Susan M Schwager

1 reference

3 September 2017

9

Stephanie J Lee

1 reference

3 September 2017

Terra L Lasho

2

1 reference

3 September 2017

Jacob S Strand

4

1 reference

3 September 2017

Michelle Elliott

5

1 reference

3 September 2017

Ruben Mesa

6

1 reference

3 September 2017

Chin-Yang Li

7

1 reference

3 September 2017

D Gary Gilliland

10

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

3 September 2017

1 reference

3 September 2017

volume

106

1 reference

3 September 2017

issue

3

1 reference

3 September 2017

page(s)

631-635

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

Identification of an acquired JAK2 mutation in polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21645

7 January 2021

Identifiers

DOI

10.1002/CNCR.21645

1 reference

3 September 2017

1 reference